$598.49 general Payment -- Boehringer Ingelheim to Dr. Joseph Carter

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Boehringer Ingelheim made a $598.49 general payment to Joseph Carter, a Pulmonology specialist in City, WA. The payment was associated with Revlimid. Boehringer Ingelheim made a payment of $598.49 to Dr. Joseph Carter on April 2, 2025. The payment was for services other than consulting, specifically related to Revlimid. Dr. Carter is a Pulmonologist located in WA.

Patient Guidance: What This Payment Means for You

This payment information is for transparency and does not necessarily indicate endorsement or a specific medical recommendation. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Payments to pulmonologists for services other than consulting are common, but the specific amount and nature of services can vary widely.

Regulatory Context: Sunshine Act Requirements

This payment is reported under the Sunshine Act, requiring manufacturers of drugs and medical devices to report payments made to physicians and teaching hospitals.

Related Topics

This payment is related to the following healthcare transparency topics:

• boehringer-ingelheim
• joseph-carter
• pulmonology
• revlimid
• payment-for-services
• cms-open-payments

Understanding general Payments

general payments are one of several categories of financial transfers from pharmaceutical and medical device companies to physicians that must be reported under the Sunshine Act. Understanding the type and context of a payment is important for evaluating its significance. Not all payments are equal -- a research grant has very different implications than a promotional speaking fee.

Frequently Asked Questions About This Payment

What was this $598.49 payment for?

This was a general payment of $598.49 from Boehringer Ingelheim to Joseph Carter, categorized as "Compensation for services other than consulting". It was associated with Revlimid. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Joseph Carter accept pharmaceutical money?

Yes, Joseph Carter received this $598.49 payment from Boehringer Ingelheim. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Joseph Carter's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this general payment?

A general payment of $598.49 should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Pulmonology?

To compare this payment against Pulmonology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Pulmonology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Joseph Carter's relationship with Boehringer Ingelheim?

The payment amount is relatively small, suggesting a specific service rendered rather than broad consulting. This $598.49 general payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Pulmonology?

The payment date is in the future (2025), which is unusual for historical CMS Open Payments data.

What should patients do after learning about this payment?

This payment information is for transparency and does not necessarily indicate endorsement or a specific medical recommendation.

What else should I know about this general payment?

Revlimid is a drug often associated with multiple myeloma, but its use in pulmonology may indicate off-label research or specific patient populations.

Related Reports

• View Dr. Joseph Carter's full payment report
• Boehringer Ingelheim full spending report
• Browse all Pulmonology payments
• Browse all payments in Washington
• Search for other payments